| Date | Time | Source | Announcement |
|---|---|---|---|
| 18 Oct 1999 | 11:00 AM | Omeprazole Patent Upheld | |
| 08 Oct 1999 | 03:33 PM | Notice of Quarterly Rslts | |
| 20 Sep 1999 | 01:30 PM | Drug Approval | |
| 17 Sep 1999 | 03:52 PM | Arimidex Data | |
| 09 Sep 1999 | 08:51 AM | Preliminary Injunctions | |
| 31 Aug 1999 | 04:54 PM | Interim Dividend Notification | |
| 26 Aug 1999 | 04:00 PM | Directors' Dealings | |
| 23 Aug 1999 | 08:00 AM | Prilosec US Patent Cases | |
| 19 Aug 1999 | 09:00 AM | Injunction Upheld | |
| 03 Aug 1999 | 07:34 AM | First Interim Dividend | |
| 03 Aug 1999 | 07:33 AM | Interim Results - Part 3 | |
| 03 Aug 1999 | 07:32 AM | Interim Results - Part 2 | |
| 03 Aug 1999 | 07:31 AM | Interim Results - Part 1 |
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
Astra Zeneca share price launched at 605p in 1993.